alnylam corporate presentation 2023

• About Alnylam
• Diversity, Equity & Inclusion
• Patient Access Philosophy
• Corporate Responsibility
• Transparency
• Grants & Giving
• Advocacy for Impact Grants
• Investigator Initiated Studies (IIS)
• The Science of RNAi
• Delivery Platforms
• Therapeutic Areas
• Clinical Trials
• Scientific Advisory Board
• Intellectual Property
• Capella (Scientific Presentations)
• Product Listing
• Press Releases
• For Investors
• Stock Information
• Investors Toolkit
• Events & Presentations
• Financial Information
• SEC Filings
• Corporate Governance
• Analyst Coverage
• Fundamentals
• Ownership Profile
• Annual Meetings
• For Medical Professionals
• Genetic Testing & Counseling
• Early Access Program
• Givosiran Early Access
• Patisiran Early Access
• Lumasiran Early Access
• Medical Publication Support
• For Patients
• Amyloidosis
• Acute Hepatic Porphyria
• Primary Hyperoxaluria
• Patient Services
• Genetic Testing and Counseling
• Patient Advocacy
• Working at Alnylam
• Career Opportunities
• Search Jobs
• Medical Resources (RNAi Science)

Jun 05, 2023 Press Release for Alnylam

Alnylam to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare Conference

Jun 05, 2023

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 5, 2023-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman Sachs 44 th Annual Global Healthcare Conference on Monday, June 12, 2023 at 8:00 am PT ( 11:00 am ET ) at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA.

A live audio webcast of the presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events . A replay will be available on the Alnylam website within 48 hours after each event.

About Alnylam Pharmaceuticals Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO ® (patisiran), AMVUTTRA ® (vutrisiran), GIVLAARI ® (givosiran), OXLUMO ® (lumasiran), and Leqvio ® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “ Alnylam P 5 x25 ” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam , on LinkedIn , or on Instagram .

View source version on businesswire.com : https://www.businesswire.com/news/home/20230605005662/en/

Christine Regan Lindenboom (Investors and Media) 617-682-4340

Josh Brodsky (Investors) 617-551-8276

Source: Alnylam Pharmaceuticals, Inc.

For Media Inquiries, please contact:

Christine Lindenboom

SVP, Investor Relations & Corporate Communications [email protected] 617-682-4340

For Investor Inquiries, please contact:

Josh Brodsky

VP, Investor Relations & Corporate Communications [email protected] 617-551-8276

Essential assets and documents related to Alnylam

VIEW ALL PRESS RELEASES

Visit our social channels to learn more about the innovative work we are doing at Alnylam.